Roivant Sciences Ltd
ROIV
Closed
$36.36
Closed
-(-)
At close
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply
About
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. The company also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Key stats
Open
$36.95
Volume
6.19M
Market cap
$26.22B
Prev. close
$36.29
Impl / hst vl
-
Open interest
$0.00
$36.22
Day’s Range
$37.29
$20.78
52W Range
$37.97
Valuation
44
Valuation score
Fairly Valued
P/E
-
P/S
3,479.27
P/B
6.19
Current ratio
16.72
Debt / Equity
-0.30
ROE
-6.12%
Gross margin
80.31%
Income growth
-162.65%
FCF growth
64.12
Analysts estimates
Consensus rating
Buy
The average rating from top 9 analysts indicates that stock is expected to perform in line with the market
Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$38.93
The top 14 analysts forecasts that 12-month price may increase by 7.05%, with a low of $34.34 and a high of $44.10
$34.34
Low
$38.93
Avg
$44.10
High
Current price
Earnings
Q2 ‘26 revenue
$1.44M
Q2 ‘26 net income
-$189.84M
Revenue
Net income
Previous EPS
-$0.17
Estimate EPS
-$0.32
Actual EPS
Estimate EPS
Explore the Healthcare sector
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply